Friday, January 04, 2008
Drug Company Marketing Expenditures
How about $57 billion or so annually? More coming in a few days. In the meantime, read this and see what you think.
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Email
Psychiatric medications, science, marketing, psychiatry in general, and occasionally clinical psychology. Questioning the role of key opinion leaders and the use of "science" to promote commercial ends rather than the needs of people with mental health concerns.
Blog Archive
-
▼
2008
(103)
-
▼
January
(17)
- Peer Review, GSK, Cash, and Limp Noodles
- Fred Hassan's Hindquarters: Meet Peter Rost's Boot
- The Serotonin Monster Strikes Again
- Bribing Physicians: Where My Money At?
- My Political Leanings Are Out in the Open (Sort of)
- Key Opinion Leaders, Continuing Medical Education,...
- Defending the Hiding of Negative Clinical Trial Data
- Risperdal for Depression: A Depressing Look
- Antidepressants: Hiding and Spinning Negative Data
- Antidepressants: You Dropped a Bomb on Me
- Zetia: Just the Latest Chapter in Hiding Data
- Zetia, Paxil, Medical Journals, Fraud, Etc,
- Big Pharma: Marketing Ain't Cheap
- Inaccurate Advertising Hurts
- Drug Company Marketing Expenditures
- Mandatory Mental Health Screening for Massachusett...
- Risperdal for Depression Study Hammered Yet Again
-
▼
January
(17)
Academia
Pharma: General
Psychiatry and Psychology
Scientific Misconduct
About Me
- CL Psych
- I'm an academic with a respectable amount of clinical experience and no drug industry funding. Given my lack of time, don't expect multiple daily updates. Certain things about clinical psychology, the drug industry, psychiatry, and academics drive me nuts, and you'll probably pick up on these pet peeves before long...
Translate this page
Subscribe Via Email
No comments:
Post a Comment